Abstract
Since transforming growth factor β (TGF-β) is presumed to play a role in lung fibrosis, we evaluated the effect of suramin (Sur), a substance with an anti-TGF-β effect, in vivo on bleomycin (Bleo)-induced pulmonary injury in mice and in vitro on human lung fibroblasts. Four groups of C57BL/6 mice each received one of four treatments: (1) intratracheal (IT) instillation of Bleo and intraperitoneal (IP) injections of Sur, every other day, starting one day before IT instillation of Bleo (Bleo-Sur); (2) IT Bleo and IP injections of saline (Bleo-Sal); (3) IT saline and IP Sur (Sal-Sur); and (4) IT and IP saline (Sal-Sal). Animals were sacrificed 14 days after IT treatment. Lung injury was evaluated by analysis of bronchoalveolar lavage (BAL) fluid, histologically by the semiquantitative morphological index, and biochemically by analysis of lung hydroxyproline content. In vitro, Sur did not affect TGF-β induced increase of α 1 (I) collagen mRNA in human lung fibroblasts. In vivo treatment of mice with Sur did not affect Bleo-induced lung injury. These results indicate that despite its potential anti TGF-β and lymphocytotoxic effects, Sur is not a therapeutic candidate drug for rescue of lung fibrosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
